• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Neptune Medical Appoints Dr. Fred Moll as Chairman of the Board

    11/20/23 8:00:00 AM ET
    $PRCT
    $SWAV
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $PRCT alert in real time by email

    Neptune Medical, a leading innovator in medical technology, is pleased to announce the appointment of Dr. Fred Moll as Chairman of the Board. Dr. Moll, a seasoned entrepreneur and influential figure in the medical technology industry considered to be the father of medical robotics, brings a wealth of experience and expertise to Neptune Medical.

    Dr. Fred Moll is currently a Managing Partner at Sonder Capital, a venture capital firm focused on investing in breakthrough healthcare technologies. His illustrious career includes founding Intuitive Surgical, a pioneer in robotic-assisted minimally invasive surgery, and Auris Health, which was acquired by Johnson & Johnson.

    In addition to his role at Sonder Capital, Dr. Moll currently serves on the boards of several healthcare companies, including Procept BioRobotics, Inc. (NASDAQ:PRCT) as Chairman, and ShockWave Medical (NASDAQ:SWAV), contributing his strategic vision and leadership to guide these companies in their respective fields.

    "We are thrilled to welcome Dr. Fred Moll as the Chairman of the Board at Neptune Medical," said Alex Tilson, Founder and CEO of Neptune Medical. "His unparalleled experience in the medical technology sector will be invaluable as we continue to grow and advance our mission of transforming healthcare with innovative products."

    As Chairman of the Board, Dr. Moll will provide strategic guidance and leadership to Neptune Medical, supporting the company in its mission to develop cutting-edge medical technologies that improve patient outcomes and enhance the efficiency of healthcare delivery across multiple clinical areas.

    "I am honored to join Neptune Medical as Chairman of the Board," said Dr. Fred Moll. "I am excited about the opportunity to work with the talented team at Neptune Medical and contribute to the development of groundbreaking medical technologies that have the potential to make a significant impact on patient care."

    About Neptune Medical

    Neptune Medical is a Burlingame, Calif.-based medical technology company dedicated to developing innovative solutions that address the challenges faced by healthcare professionals and improve patient outcomes.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231120048805/en/

    Get the next $PRCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRCT
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    PROCEPT BioRobotics Corporation
    $PRCT
    7/6/2026$25.00Buy → Hold
    Truist
    PROCEPT BioRobotics Corporation
    $PRCT
    6/24/2026$30.00Outperform
    Evercore ISI
    PROCEPT BioRobotics Corporation
    $PRCT
    6/11/2026$29.00Outperform → Market Perform
    Leerink Partners
    PROCEPT BioRobotics Corporation
    $PRCT
    3/6/2026$30.00Neutral
    Robert W. Baird
    PROCEPT BioRobotics Corporation
    $PRCT
    2/26/2026Outperform → Perform
    Oppenheimer
    PROCEPT BioRobotics Corporation
    $PRCT
    2/26/2026$20.00Neutral → Underperform
    BofA Securities
    PROCEPT BioRobotics Corporation
    $PRCT
    12/12/2025$62.00Buy
    UBS
    PROCEPT BioRobotics Corporation
    $PRCT
    12/8/2025$38.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $PRCT
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Desai Antal Rohit was granted 3,315 shares, increasing direct ownership by 9% to 38,467 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    6/10/26 4:46:13 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Director Dodrill Amy M. was granted 3,315 shares, increasing direct ownership by 43% to 10,941 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    6/10/26 4:45:01 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Director Garrett Mary was granted 3,315 shares, increasing direct ownership by 23% to 17,700 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    6/10/26 4:43:50 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Desai Antal Rohit bought $10,482,943 worth of shares (426,262 units at $24.59) (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/9/26 7:19:42 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Director Moll Frederic H bought $785,138 worth of shares (20,000 units at $39.26), increasing direct ownership by 2% to 863,159 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:18:26 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mobia Medical Appoints Reza Zadno, Ph.D., to its Board of Directors

    AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (NASDAQ:MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Reza Zadno, Ph.D., to the Board as an independent director, effective July 14, 2026. Dr. Zadno will also serve as a member of the Compensation Committee. "We are pleased to welcome Reza to the Mobia Medical Board of Directors," said Richard Foust, President and Chief Executive Officer of Mobia Medical. "He has built and scaled multiple public medical technology companies, and his operational perspective and public company governance experience wi

    7/15/26 4:05:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026

    SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2026 after market close on Tuesday, August 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/8fznodv2 Dial-in registration for sell-side research ana

    7/14/26 4:05:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

    SAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation® therapy versus radical prostatectomy, and FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablation therapy versus active surveillance. The first randomized WATER IV study (WATER IV RP) fully enrolled 280 planned patients and is the only FDA randomized study comparing Aquablation therapy to radical prostatectomy, the established surgical standard of care. Based on current timelines, the Company e

    5/28/26 8:00:00 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    $SWAV
    SEC Filings

    View All

    PROCEPT BioRobotics Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)

    6/10/26 4:33:57 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by PROCEPT BioRobotics Corporation

    SD - PROCEPT BioRobotics Corp (0001588978) (Filer)

    6/1/26 5:27:17 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by PROCEPT BioRobotics Corporation

    SCHEDULE 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    5/18/26 1:22:47 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PROCEPT BioRobotics downgraded by Truist with a new price target

    Truist downgraded PROCEPT BioRobotics from Buy to Hold and set a new price target of $25.00

    7/6/26 8:45:49 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on PROCEPT BioRobotics with a new price target

    Evercore ISI initiated coverage of PROCEPT BioRobotics with a rating of Outperform and set a new price target of $30.00

    6/24/26 8:43:50 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded PROCEPT BioRobotics from Outperform to Market Perform and set a new price target of $29.00

    6/11/26 8:05:24 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    Mobia Medical Appoints Reza Zadno, Ph.D., to its Board of Directors

    AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (NASDAQ:MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Reza Zadno, Ph.D., to the Board as an independent director, effective July 14, 2026. Dr. Zadno will also serve as a member of the Compensation Committee. "We are pleased to welcome Reza to the Mobia Medical Board of Directors," said Richard Foust, President and Chief Executive Officer of Mobia Medical. "He has built and scaled multiple public medical technology companies, and his operational perspective and public company governance experience wi

    7/15/26 4:05:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Bruker Appoints Laura Francis to its Board of Directors

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

    2/21/25 8:00:00 AM ET
    $BRKR
    $PGNY
    $SIBN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Misc Health and Biotechnology Services
    Health Care

    $PRCT
    $SWAV
    Financials

    Live finance-specific insights

    View All

    PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026

    SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2026 after market close on Tuesday, August 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/8fznodv2 Dial-in registration for sell-side research ana

    7/14/26 4:05:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics Reports First Quarter 2026 Financial Results

    SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2026. "Over the past six months, we have taken decisive actions to reset the organization by sharpening our focus on operational excellence, accountability, and commercial discipline, and our first quarter results reflect the early impact of that work," said Larry Wood, Chief Executive Officer. "We delivered $83.1 million in revenue, driven by strong U.S. system sales and improved pricing.

    4/29/26 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026

    SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2026 after market close on Wednesday, April 29, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/rdtftqik/ Dial-in registration for sell-side research

    4/9/26 4:05:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/14/24 1:28:32 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/12/24 5:01:10 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/4/24 1:31:19 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care